New Raman Microscope Enables High-Resolution Materials Analysis
Materials scientists, engineers, and academic researchers can accelerate their research and understand materials in applications ranging from pharmaceutical formulation and life sciences to semiconductor manufacturing and geology using a new Raman imaging microscope. The microscope is so easy to operate that scientists of all abilities can simply walk up and use it to produce stunning chemical images without learning a new technique.
Designed to quickly reveal molecular structure, chemical composition and sample morphology, the Thermo Scientific DXRxi Raman imaging microscope can provide new insights, identify defects and confirm product quality with a high degree of confidence. By employing the image-centric software interface, users can quickly profile materials through information-rich chemical images.
Instant visual feedback and instinctive image-driven control separates this instrument from other Raman microscopes. The DXRxi microscope can analyze large areas, providing microscopic detail in just seconds. Organizations with multiple disciplines can leverage the simplicity and approachability of the DXRxi microscope to realize an immediate impact in research output.
“The DXRxi microscope enables scientists to find the needle in a haystack quickly,” said Ryan Kershner, product manager, Raman spectroscopy, Thermo Fisher Scientific. “Because this high-powered microscope is so simple to operate, students and expert microscopists can rapidly collect data and answer complex questions in a variety of fields, from biological tissue to carbon nanotube research.”
The DXRxi microscope offers the following features:
• New Thermo Scientific OMNICxi image-centric software provides visually driven data acquisition and intuitive sample targeting and parameter optimization
• Automated alignment and calibration saves time and frustration
• Near-instant visual chemical profiling requires no spectroscopic expertise to interpret
• Ability to analyze large samples quickly
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.